Charles Schwab Investment Management Inc Checkpoint Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 16, 2021	BUY	$2.5 - $3.53 $41,922 - $59,194	16,769 Added 98.97%	33,712 $112,000
Q2 2021 Aug 16, 2021	SELL	$2.36 - $3.2 $254,787 - $345,475	-107,961 Reduced 86.44%	16,943 $50,000
Q1 2021 May 17, 2021	SELL	$2.6 - $4.16 $33,183 - $53,094	-12,763 Reduced 9.27%	124,904 $393,000
Q4 2020 Feb 16, 2021	BUY	$2.19 - $2.96 $30,703 - $41,499	14,020 Added 11.34%	137,667 $365,000
Q3 2020 Nov 13, 2020	BUY	$1.62 - $4.24 $9,506 - $24,880	5,868 Added 4.98%	123,647 $332,000
Q2 2020 Aug 14, 2020	BUY	$1.19 - $2.27 $50,658 - $96,633	42,570 Added 56.6%	117,779 $234,000
Q1 2020 May 15, 2020	BUY	$1.11 - $2.43 $30,237 - $66,195	27,241 Added 56.79%	75,209 $114,000
Q2 2019 Aug 09, 2019	BUY	$2.75 - $5.0 $86,325 - $156,955	31,391 Added 189.36%	47,968 $146,000
Q1 2019 May 14, 2019	BUY	$2.01 - $4.01 $33,319 - $66,473	16,577 New	16,577 $48,000

1.91M

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $297M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.